In contrast, a placebo controlled RCT of men with prostate cancer treated with luteinizing hormone releasing hormone (LHRH) agonist (n = 24) revealed a significant improvement with methylphenidate 5–10 mg/day for 10 weeks [35]. Here, GNRH1 is linked to prostate cancer.